$0.40
+0.02 (+6.29%)
Open$0.34
Previous Close$0.37
Day High$0.43
Day Low$0.33
52W High$1.28
52W Low$0.30
Volume—
Avg Volume786.7K
Market Cap4.72M
P/E Ratio—
EPS$-0.90
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,362.8% upside
Current
$0.40
$0.40
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.32M | 8.67M | 3.80M |
| Net Income | -18,772,018 | -12,942,252 | 985.2K |
| Profit Margin | -800.8% | -760.7% | 25.9% |
| EBITDA | -28,579,597 | -20,798,695 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +30.5% | +30.5% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |